JNJ Stock Recent News

Johnson & Johnson remains undervalued with strong profitability and reasonable valuation metrics, but growth prospects are modest and uncertain. Profitability is robust, with an A+ grade, high margins, and nearly 30% return on equity, supporting the company's structural quality. Key risks include regulatory challenges, legal liabilities from talc lawsuits, and potential price controls on major drugs like Darzalex Faspro.

CNBC's Angelica Peebles and Johnson & Johnson chairman and CEO Joaquin Duato join 'Squawk Box' to discuss the company's 5-year multiple myeloma treatment study, the company's cancer treatments, M&A outlook, 'most favored nation' pricing, and more.

It may be too soon to rotate back into the risk trade as market volatility calms.

Some of the best dividend stocks in the world are on sale right now. Shares of Federal Realty Investment Trust (FRT -0.30%), Johnson & Johnson (JNJ -0.56%), and PepsiCo (PEP -0.56%) are currently down 8% to 27% from their 52-week highs.

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Wednesday, July 16th to review second-quarter results. Joaquin Duato, Chairman and Chief Executive Officer, Joseph J. Wolk, Executive Vice President and Chief Financial Officer and Darren Snellgrove, Vice President, Investor Relations will host the call. The question and answer portion of the call will also include additional members of Johnson & J.

Johnson & Johnson (NYSE:JNJ ) Bernstein's 41st Annual Strategic Decisions Conference Call May 28, 2025 9:00 AM ET Company Participants Joaquin Duato - Chairman and Chief Executive Officer Joseph Wolk - Executive Vice President, Chief Financial Officer Conference Call Participants Lee Hambright - Bernstein Lee Hambright All right, thank you, everybody. Thanks, guys.

Market uncertainty and muted returns in 2025 make portfolio stability and income reliability crucial; dividend stocks are key for navigating volatility. General Mills offers a well-covered 4.4% yield, strong fundamentals, and attractive long-term value despite near-term headwinds and potential price weakness. Kenvue, with a 3.4% yield and resilient performance post-spin-off, provides stability and potential for gradual dividend growth and price appreciation.

Despite legal headwinds and a declining share price, JNJ remains a financial powerhouse with strong profitability, a robust dividend, and aggressive buybacks. JNJ's 62-year streak of dividend growth, 3.4% yield, and disciplined capital allocation make it highly attractive for long-term, income-focused investors. The company is undervalued, trading at less than 15x 2025 EPS, with double-digit EPS growth projected and a pipeline of high-growth assets fueling future expansion.

There are hundreds of dividend stocks on the market, but they don't all offer the same level of security. Some haven't increased their payouts in years.

I maintain my buy rating on JNJ, citing attractive valuation, improved technicals, and a raised intrinsic value target of $184 per share. JNJ's recent earnings beat expectations, with strong Medicine and MedTech growth, a 63rd consecutive dividend hike, and healthy free cash flow. Litigation headwinds are easing, and management raised revenue guidance, though they remain cautious on earnings due to tariffs and acquisitions.